Skip to content

Efavirenz may linger for up to eight weeks after treatment stops

Treatment interruption delivers no benefit for most heavily treated, despite resistance loss

South African union boss attacks government `betrayal` on AIDS

Discordant CD4 increase of 25 cells/mm3 confers clinical benefit despite advanced disease

HCV/HIV coinfection guidelines may lead to unnecessarily premature HAART discontinuation

Cryptococcal meningitis: treatment needs to be cheaper and more available

Revised 2005 WHO guidelines on prevention of mother-to-child transmission

GSK halts chemokine inhibitor trial due to safety fears

Free ARVs should not be restricted to treatment-naïve, say Ugandan doctors